

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jenny Nyberg et al.

Application No.: 10/518,159

Confirmation No.: 7593

Filed: January 18, 2005

Art Unit: 1649

For: USE OF COMPOUNDS HAVING GIP
ACTIVITY FOR THE TREATMENT OF
DISORDERS ASSOCIATED WITH
ABNORMAL LOSS OF CELLS AND/OR FOR
THE TREATMENT OF OBESITY

Examiner: Daniel E. Kolker

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Official Action mailed by the U.S. Patent and Trademark Office on March 19, 2006, please consider the accompanying remarks. Reconsideration of the pending application in view of the following remarks is requested.

The Examiner has required restriction to one of the following 13 claim groups:

Group 1: Claims 1-13 and 22-30, drawn to methods of administering compounds with identical or similar effects as SEQ ID NO:2 or 4, to the extent that the claims encompass administration of proteins;